Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016924 · ClinicalTrials.gov registry record · Phase 2
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
A Phase 2 study of HIV Infections and Acquired Immune Deficiency Syndrome (AIDS), sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT02016924 is a Phase 2 study of HIV Infections and Acquired Immune Deficiency Syndrome (AIDS) that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 133 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02016924, a Phase 2 study of HIV Infections and Acquired Immune Deficiency Syndrome (AIDS), is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.
Conditions Studied
Interventions
- DRUG BR
- DRUG ATV
- DRUG DRV
- DRUG Cobicistat
- DRUG F/TAF
Study Locations (20)
Other
- Hospital General de Agudos Cosme Argerich - Buenos Aires
- Helios Salud - Buenos Aires
- University of the Free State - Bloemfontein
- University of Stellenbosch - Cape Town
- King Edward VIII Hospital - Durban
- Rahima Clinical Trials, a Division of Wits Health Consortium (Pty) Ltd - Johannesburg
- The Aurum Institute: Pretoria Clinical Research Centre - Pretoria
- Perinatal HIV Research Unit - Soweto
- HIV-NAT - Bangkok
- Siriraj Hospital - Bangkok
- Srinagarind Hospital - Khon Kaen
- MU-JHU Research Collaboration/MU-JHU Care Ltd - Kampala
- SICRA-TASO Mulago National Referral Hospital - Kampala
California
- Pediatric Infectious Disease Associates - Long Beach
- Peter Morton Medical Building - Los Angeles
Colorado
- University of Colorado Denver - Aurora
District of Columbia
- The George Washington University - Washington D.C.
Florida
- University of South Florida - Tampa
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- University of Texas Health Science Center of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2014-01-16 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016924
The ClinicalTrials.gov registry entry for NCT02016924 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (70% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which BR is the first listed.
NCT02016924 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02016924 about?
NCT02016924 is a clinical study titled "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV". The goal of this clinical study is to learn more about the safety and dosing of study drugs, cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted darunavir (DRV/co) and emtricitabine/tenofovir alafenamide (F/TAF), in children (age ≥ 4 weeks to \< 18 years) with HIV.
What is the current status of trial NCT02016924?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2014-01-16. Estimated completion is 2027-03.
What conditions does trial NCT02016924 study?
This clinical trial studies the following conditions: HIV Infections, Acquired Immune Deficiency Syndrome (AIDS).
What interventions are being tested in trial NCT02016924?
The interventions under investigation include: BR (DRUG), ATV (DRUG), DRV (DRUG), Cobicistat (DRUG), F/TAF (DRUG).
Who is sponsoring clinical trial NCT02016924?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02016924 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
HIV Infections
All registered trials for this condition
Acquired Immune Deficiency Syndrome (AIDS)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.